毒理性
◉ 母乳喂养期间使用总结：奥曲肽进入母乳的情况尚未进行研究。然而，由于其分子量高达1019道尔顿，它很可能不易被排入母乳中。它口服吸收不良，已经通过注射直接安全地给予婴儿，因此不太可能对哺乳婴儿产生不利影响。至少有3名婴儿成功母乳喂养，没有报告不良反应。在获得更多数据之前，应谨慎在哺乳母亲中使用奥曲肽，并密切监测婴儿，特别是如果婴儿年龄在2个月以下。
◉ 对哺乳婴儿的影响：一名孕妇在怀孕期间和产后使用奥曲肽治疗肢端肥大症（剂量未说明）。她母乳喂养了4个月的婴儿，婴儿未发现明显问题。
一名患有肢端肥大症的女性在产后每6周注射一次长效奥曲肽（善龙；剂量未说明）的同时进行母乳喂养。产后6个月，注射频率增加到每4周一次。她母乳喂养了12个月的婴儿（喂养程度未说明）。在孩子5岁时，发育正常。
◉ 对泌乳和母乳的影响：一名患有肢端肥大症的孕妇在怀孕12周开始每月使用长效奥曲肽10毫克。分娩后，她一直母乳喂养到产后6周，当时她需要将奥曲肽LAR增加到每月20毫克。她继续成功地使用奥曲肽进行母乳喂养。
◉ Summary of Use during Lactation:The excretion of octreotide into breastmilk has not been studied. However, because it has a high molecular weight of 1019 daltons it is likely to be poorly excreted into breastmilk. It is poorly absorbed orally and has been safely administered directly to infants by injection, so it is unlikely to adversely affect the breastfed infant. At least 3 infants have been successfully breastfed with no adverse effects reported. Until more data are available, octreotide should be used in nursing mothers with careful infant monitoring, especially if the infant is under 2 months of age.
◉ Effects in Breastfed Infants:One mother was treated for acromegaly during pregnancy and postpartum with octreotide (dose not stated). She breastfed (extent not stated) her infant for 4 months with no apparent problems noted in the infant.
A woman with acromegaly took long-acting octreotide (Sandostatin LAR; dose not stated) every 6 weeks postpartum while breastfeeding. At 6 months postpartum, the frequency of the injections was increased to every 4 weeks. She breastfed her infant (extent not stated) for 12 months. At age 5 years the child had developed normally.
◉ Effects on Lactation and Breastmilk:A pregnant woman with acromegaly started long-acting octreotide 10 mg monthly at 12 weeks gestation. After delivery, she breastfed her until 6 weeks postpartum when she required an increase in octreotide LAR to 20 mg monthly. She continued to breastfeed successfully on octreotide.
来源:Drugs and Lactation Database (LactMed)
